Renal cell carcinoma
Renal cell carcinoma
Updated: 05/05/2021
© Jun Wang, MD, PhD
General features
- Most common type of kidney cancer in adults
- Usually > 60 years old, but younger if in familial clusters
- More common in male
- Rarely bilateral
- More common in people of Northern European ancestry (Scandinavians) and North Americans
- In the US, slightly more common in blacks
Risk factors
- Tobacco: Most significant risk factor
- Obesity, especially in women
- Hypertension
- Longer usage of NSAID
- Long term renal dialysis, probably associated with acquired cystic disease
- Kidney transplantation
- Genetic disorders: von Hippel-Lindau syndrome, hereditary papillary renal carcinoma, Birt-Hogg-Dube syndrome, and hereditary leiomyomatosis and renal cell cancer syndrome
Clinical features
- Various, most asymptomatic until advanced stage
- Flank pain
- Hematuria
- Abdominal mass
- Vascular manifestations: scrotal varicocele, inferior vena cava involvements (edema, ascites, abnormal liver functions, etc)
- Paraneoplastic symptoms: Anemia, weight loss, hypertension, hepatic dysfunctions, fever, erythrocytosis, etc
- Metastasis: common, most commonly in lung, bones, may occur long time after treatment (anytime, anywhere)
Classification
- Clear cell type renal cell carcinoma
- Chromophobe cell type renal cell carcinoma
- Papillary type renal cell carcinoma
- Collecting duct carcinoma
- Xp11 translocation/MiT family translocationrenal cell carcinomas
- Medullary carcinoma
- Multilocular cystic renal neoplasm of low malignant potential
- Hereditary leiomyomatosis and renal cell carcinoma associated renal cell carcinoma
- Renal medullary carcinoma
- Succinate dehydrogenase deficient renal cell carcinoma
- Mucinous tubular and spindle cell carcinoma
- Tubulocystic renal cell carcinoma
- Acquired cystic disease-associated renal cell carcinoma
- Clear cell papillary renal cell carcinoma
- Renal cell carcinoma, unclassified
- Positive: PAX8
- Negative: Uroplakin (positive for urothelial carcinoma)
Markers
- Positive: PAX8
- Negative: Uroplakin (positive for urothelial carcinoma)
- Image studies
- Biopsy
Treatment
- Localized tumor: Surgery, cryotherapy, radiofrequency ablation, adjuvant therapy (immunotherapy, antiangiogenic therapy)
- Advance tumor: Immunotherapy, molecular targeted therapy (VEGF inhibitor, mTOR inhibitor)
Back to kidney masses
Back to contents
Comments
Post a Comment